company background image

Otonomy NasdaqGS:OTIC Stock Report

Last Price


Market Cap







26 Sep, 2022


Company Financials +
OTIC fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health4/6

OTIC Stock Overview

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States.

Otonomy Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Otonomy
Historical stock prices
Current Share PriceUS$0.28
52 Week HighUS$2.59
52 Week LowUS$0.24
1 Month Change-32.07%
3 Month Change-87.34%
1 Year Change-85.64%
3 Year Change-88.35%
5 Year Change-91.81%
Change since IPO-98.38%

Recent News & Updates

Aug 01

Otonomy crashes 73% as mid-stage trial for tinnitus candidate fails

The shares of neurology focused Otonomy (NASDAQ:OTIC) plunged ~73% in the pre-market Monday after the company said its Phase 2 trial for OTO-313 did not demonstrate a clinically meaningful benefit for OTO-313 compared to placebo in hearing disorder tinnitus. "These results were unexpected with a much higher placebo response than observed in the prior Phase 1/2 study,” Chief Executive David A. Weber noted, adding that the company would discontinue further development of OTO-313 and take other steps to extend cash runway. This is a developing story. Check back for more updates.

Jul 25

Otonomy GAAP EPS of -$0.19 beats by $0.01

Otonomy press release (NASDAQ:OTIC): Q2 GAAP EPS of -$0.19 beats by $0.01. Cash Position: Cash, cash equivalents, and short-term investments totaled $53.1 million as of June 30, 2022, compared to $77.4 million as of December 31, 2021. Outlook: Financial Guidance: Otonomy expects that GAAP operating expenses for 2022 will be in the range of $52-$54 million, and that non-GAAP operating expenses will be in the range of $42-$44 million.

Shareholder Returns

OTICUS PharmaceuticalsUS Market

Return vs Industry: OTIC underperformed the US Pharmaceuticals industry which returned 2.9% over the past year.

Return vs Market: OTIC underperformed the US Market which returned -23% over the past year.

Price Volatility

Is OTIC's price volatile compared to industry and market?
OTIC volatility
OTIC Average Weekly Movement29.3%
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: OTIC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 29% a week.

Volatility Over Time: OTIC's weekly volatility has increased from 17% to 29% over the past year.

About the Company

200851David Weber

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss.

Otonomy Fundamentals Summary

How do Otonomy's earnings and revenue compare to its market cap?
OTIC fundamental statistics
Market CapUS$15.87m
Earnings (TTM)-US$53.09m
Revenue (TTM)n/a


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OTIC income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$53.09m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.93
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio50.1%

How did OTIC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is OTIC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OTIC?

Other financial metrics that can be useful for relative valuation.

OTIC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does OTIC's PB Ratio compare to its peers?

OTIC PB Ratio vs Peers
The above table shows the PB ratio for OTIC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average3.5x
MJNE MJ Holdings
ONTX Onconova Therapeutics
COCP Cocrystal Pharma
ADMP Adamis Pharmaceuticals
OTIC Otonomy

Price-To-Book vs Peers: OTIC is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (3.5x).

Price to Earnings Ratio vs Industry

How does OTIC's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Book vs Industry: OTIC is good value based on its Price-To-Book Ratio (0.5x) compared to the US Pharmaceuticals industry average (1.7x)

Price to Book Ratio vs Fair Ratio

What is OTIC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OTIC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate OTIC's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of OTIC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OTIC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OTIC's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Otonomy forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OTIC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OTIC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OTIC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OTIC is forecast to have no revenue next year.

High Growth Revenue: OTIC is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OTIC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Otonomy performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: OTIC is currently unprofitable.

Growing Profit Margin: OTIC is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: OTIC is unprofitable, but has reduced losses over the past 5 years at a rate of 14.8% per year.

Accelerating Growth: Unable to compare OTIC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OTIC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).

Return on Equity

High ROE: OTIC has a negative Return on Equity (-165.51%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Otonomy's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: OTIC's short term assets ($56.3M) exceed its short term liabilities ($11.7M).

Long Term Liabilities: OTIC's short term assets ($56.3M) exceed its long term liabilities ($27.0M).

Debt to Equity History and Analysis

Debt Level: OTIC has more cash than its total debt.

Reducing Debt: Insufficient data to determine if OTIC's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OTIC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: OTIC has less than a year of cash runway if free cash flow continues to grow at historical rates of 17.3% each year.

Discover healthy companies


What is Otonomy current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Otonomy Dividend Yield vs Market
How does Otonomy dividend yield compare to the market?
SegmentDividend Yield
Company (Otonomy)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (Otonomy)n/a

Notable Dividend: Unable to evaluate OTIC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OTIC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OTIC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OTIC's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OTIC has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


David Weber (62 yo)





Dr. David Allen Weber, Ph D., has been the Chief Executive Officer and President of Otonomy, Inc. since November 2010. Dr. Weber has been Non-Executive Director at Oculis ehf since September 2018.Dr. Webe...

CEO Compensation Analysis

David Weber's Compensation vs Otonomy Earnings
How has David Weber's remuneration changed compared to Otonomy's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$3mUS$600k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$3mUS$568k


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019US$2mUS$546k


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018US$5mUS$546k


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018n/an/a


Dec 31 2017US$2mUS$530k


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017n/an/a


Dec 31 2016US$3mUS$515k


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016n/an/a


Dec 31 2015US$800kUS$500k


Compensation vs Market: David's total compensation ($USD3.42M) is above average for companies of similar size in the US market ($USD780.01K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: OTIC's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Experienced Board: OTIC's board of directors are considered experienced (7.1 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

NasdaqGS:OTIC Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
28 Mar 22SellUS$46,295David WeberIndividual19,269US$2.41
28 Mar 22SellUS$23,159Paul CayerIndividual9,639US$2.41
28 Mar 22SellUS$13,692Robert SavelIndividual5,699US$2.41
28 Mar 22SellUS$10,538Alan FosterIndividual4,386US$2.41

Ownership Breakdown

What is the ownership structure of OTIC?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders269,3570.5%
VC/PE Firms5,600,0009.8%
General Public18,012,17731.6%
Hedge Funds22,006,83038.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 67.33% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Baker Bros. Advisors LP
RA Capital Management, L.P.
Point72 Asset Management, L.P.
5,450,000$1.5m0%no data
Adage Capital Management, L.P.
5,000,000$1.4m0%no data
Suvretta Capital Management, LLC
The Vanguard Group, Inc.
2,430,454$676.9k0%no data
Dafna Capital Management, LLC
Silverarc Capital Management, LLC
Avidity Partners Management, L.P.
Dimensional Fund Advisors LP
889,279$247.7k5.65%no data
Pivotal BioVenture Partners LLC
BlackRock, Inc.
790,821$220.2k-1.25%no data
Geode Capital Management, LLC
465,534$129.7k1.28%no data
Renaissance Technologies LLC
332,726$92.7k3.64%no data
Bridgeway Capital Management, LLC
323,500$90.1k0%no data
Atom Investors LP
State Street Global Advisors, Inc.
182,239$50.8k0%no data
J. Goldman & Co., L.P.
135,000$37.6k0%no data
Two Sigma Advisers, LP
120,200$33.5k-27.55%no data
Northern Trust Global Investments
110,902$30.9k-0.71%no data
Cambridge Investment Research Advisors, Inc.
76,720$21.4k-0.9%no data
BNY Mellon Asset Management
76,595$21.3k-1.41%no data
Susquehanna International Group, LLP, Asset Management Arm
71,744$20.0k315.11%no data
Alan Foster
69,517$19.4k0%no data
David Weber
67,311$18.7k0%no data

Company Information

Otonomy, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Otonomy, Inc.
  • Ticker: OTIC
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$15.872m
  • Shares outstanding: 56.99m
  • Website:

Number of Employees


  • Otonomy, Inc.
  • 4796 Executive Drive
  • San Diego
  • California
  • 92121
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OTICNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 2014
7OTDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2014

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/26 00:00
End of Day Share Price2022/09/26 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.